Study of BDTX-1535 in Participants With Glioblastoma or Non-Small Cell Lung Cancer

Study Name:
Study of BDTX-1535, in Participants With Glioblastoma or Non-Small Cell Lung Cancer

Targeted Disease(s):
Lung Cancer

Purpose of Study:

This is a first-in-human, open label, multicenter study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and the preliminary antitumor activity of BDTX-1535 in patients with GBM or NSCLC harboring sensitive EGFR alterations and who have disease progression following standard of care

Study Dates:
March 31, 2022 - September 30, 2024

Study Location:
Nationwide

Funding Source:
Black Diamond Therapeutics, Inc.

ClinicalTrails.gov Identifier:
NCT05256290

Contact: 
BDTX Clinical Team
ContactPhone: 617- 252-0848
ContactEmail: [email protected]

Asthma Educator Institute
, | Jul 11, 2022
Freedom From Smoking Clinic
Rochester, NY | Sep 16, 2022